Integrin αv-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen by Bao, Wenjie & Strömblad, Staffan
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
I
O
L
O
G
Y
 
©
 
 The Rockefeller University Press $8.00
The Journal of Cell Biology, Vol. 167, No. 4, November 22, 2004 745–756
http://www.jcb.org/cgi/doi/10.1083/jcb.200404018
 
JCB: ARTICLE
 
JCB 745
 
Integrin 
 
 
 
v-mediated inactivation of p53 controls a 
MEK1-dependent melanoma cell survival pathway 
in three-dimensional collagen
 
Wenjie Bao and Staffan Strömblad
 
Department of Laboratory Medicine, Karolinska Institutet, Stockholm, 141 86 Sweden
 
ntegrin 
 
 
 
v is required for melanoma cell survival and
tumor growth in various models. To elucidate integrin
 
 
 
v-mediated melanoma cell survival mechanisms, we
used a three-dimensional (3D) collagen gel model mim-
icking the pathophysiological microenvironment of malig-
nant melanoma in the dermis. We found that integrin 
 
 
 
v
inactivated p53 and that suppression of p53 activity by
dominant negative p53 or p53-small interfering RNA
obviated the need for integrin 
 
 
 
v for melanoma cell survival
in 3D-collagen and for tumor growth in vivo. This indicates
that integrin 
 
 
 
v-mediated inactivation of p53 functionally
I
 
controls melanoma cell survival. Furthermore, we found
that melanoma cell integrin 
 
 
 
v was required for MAPK
kinase (MEK) 1 and extracellular signal-regulated kinase
(ERK)1/2 activity in 3D-collagen, whereas inhibition of
MEK1 activity induced apoptosis. Surprisingly, MEK1 and
ERK1/2 activities were restored in integrin 
 
 
 
v-negative
melanoma cells by suppression of p53, whereas concomi-
tant block of MEK1 induced apoptosis. This suggests that
integrin 
 
 
 
v controls melanoma cell survival in 3D-collagen
through a pathway involving p53 regulation of MEK1
signaling.
 
Introduction
 
Integrins play critical roles for the regulation of tumor growth
and invasion (Hood and Cheresh, 2002). For example, expression
of integrin 
 
 
 
v
 
 
 
3 has been linked to malignant melanoma
progression, in which the vertical growth phase of dermal
malignant melanoma displays high expression levels of integrin
 
 
 
v
 
 
 
3 as compared with horizontally growing melanoma in the
epidermis (Albelda et al., 1990; Van Belle et al., 1999). Moreover,
in vivo gene delivery of integrin 
 
 
 
3 promoted invasive melanoma
growth from the epidermis into the dermis in three-dimensional
(3D) skin reconstructs (Hsu et al., 1998). Consistently, integrin
 
 
 
v controls melanoma tumorigenicity (Felding-Habermann et
al., 1992), by promoting melanoma cell survival as shown in a
3D collagen gel model in vitro, and in full thickness human
skin in vivo (Montgomery et al., 1994; Petitclerc et al., 1999).
Importantly, block of integrin 
 
 
 
v
 
 
 
3 by an antagonistic anti-
integrin 
 
 
 
v
 
 
 
3 mAb induced melanoma cell apoptosis and
thereby prevented melanoma tumor growth in mice, whereas
reconstitution of the integrin 
 
 
 
v subunit into 
 
 
 
v-negative mela-
noma cells rescued cell survival in 3D-collagen as well as in
human dermis and thereby restored melanoma tumor growth in
vivo (Montgomery et al., 1994; Petitclerc et al., 1999). However,
it is unclear how integrin 
 
 
 
v may promote melanoma cell
survival within 3D microenvironments.
Integrin-mediated cell–matrix interactions trigger a variety
of signaling pathways (Giancotti and Ruoslahti, 1999). Signal
transduction in cells within 3D-matrices appears to be markedly
different from signaling events in cells attached onto two-
dimensional (2D) substrates (Cukierman et al., 2002). For
example, tyrosine phosphorylation of FAK and EGF-receptor
signaling was different in response to cell adhesion within 3D-
matrices as compared with attachment to 2D substrates coated
onto tissue culture plates (Wang et al., 1998; Cukierman et al.,
2001). The integrin-induced MAPK kinase (MEK)-extracellular
signal-regulated kinase (ERK) MAPK cascades are key signal-
ing pathways involved in the regulation of adhesion-dependent
cell growth and survival (Howe et al., 2002). In melanoma
cells, MEK and ERK1/2 can be activated by active mutations
of BRAF in 2D cultures (Satyamoorthy et al., 2003). Given that
BRAF is mutated in most melanomas, BRAF-dependent MEK
activation might be associated with oncogenic behavior of
melanoma (Smalley, 2003). However, the role of the Raf–MEK1–
ERK1/2 pathway in the regulation of melanoma growth and
cell survival is not well characterized. Furthermore, although
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cell anchorage is needed for activating ERK1/2 in melanocytes
(Conner et al., 2003), it is unclear if integrin 
 
 
 
v may regulate mel-
anoma cell MEK1–ERK1/2 activity within 3D environments and
if this may play a role for the control of melanoma cell survival.
p53-induced apoptotic cell death plays a central role for
suppression of tumor growth (Schmitt et al., 2002). Upon acti-
vation by various types of stress stimuli, p53 transcriptionally
regulates target genes, including PUMA, Apaf 1, Bax, and Bcl-2,
which critically regulate mitochondrial apoptotic cascades
(Vousden and Lu, 2002). p53 may also induce apoptosis by di-
rectly affecting mitochondria (Mihara et al., 2003). In addition,
p53 has been associated with death receptors and activation of
caspase-8 (Ashkenazi and Dixit, 1998). In angiogenesis, liga-
tion of integrin 
 
 
 
v
 
 
 
3 inactivated vascular cell p53, whereas
p53 null mice were refractory to an integrin 
 
 
 
v-antagonist that
blocked angiogenesis in wild-type (wt) mice (Strömblad et al.,
1996, 2002). Interestingly, the p53 gene is rarely mutated in
melanoma, although p53 is mutated in most human cancers
(Geara and Ang, 1996; Jenrette, 1996). Therefore, melanoma
cells typically express wt p53 protein and would because of
this be expected to be sensitive to DNA-damaging agents.
However, most melanoma cells are extremely radio resistant
and irradiation of melanoma cells expressing wt p53 leads to
accumulation of p53 but not to apoptosis (Satyamoorthy et al.,
2000). Similarly, overexpression of wt p53 by adenovirus in
melanoma cells did not induce apoptosis (Satyamoorthy et al.,
2000). However, it is unclear why melanoma cells harboring
wt p53 can still form tumors and survive. Based on our previ-
ous finding that integrin 
 
 
 
v
 
 
 
3 inhibits endothelial cell p53 ac-
tivity, and that dermal malignant melanoma express high levels
of integrin 
 
 
 
v
 
 
 
3, we hypothesized that melanoma cell integrin
 
 
 
v
 
 
 
3 might suppress p53 activity and thereby obviate the need
for p53 mutations.
To elucidate molecular mechanisms for how integrin
 
 
 
v
 
 
 
3 may promote melanoma cell survival, we used a 3D
dermal collagen type I gel model because 3D cell culture sys-
tems are capable to provide distinct advantages as compared
with 2D systems for studying cellular behavior in a 3D tissue-
like context (Zahir and Weaver, 2004). For example, a 3D
laminin-rich basement membrane model has been effectively
used to examine mammary epithelial cell morphogenesis, po-
larity, differentiation, proliferation, and survival (Bissell et
al., 2002; Zahir and Weaver, 2004). The model with a dermal
3D collagen type I gel that we used mimics the physiological
dermal microenvironment where 
 
 
 
90% of the protein is col-
lagen type I (Montgomery et al., 1994). We found that M21
and M0-
 
 
 
v melanoma cells depended on integrin 
 
 
 
v for sur-
vival in 3D-collagen. Furthermore, integrin 
 
 
 
v functionally
promoted melanoma cell survival by suppression of p53 ac-
tivity and by activation of a MEK1 signaling pathway. Impor-
tantly, our results indicate that p53 functionally acts upstream
of MEK1 in an integrin 
 
 
 
v-dependent pathway that regulates
melanoma cell survival in 3D environments, but that mela-
noma cells are independent of this pathway under 2D culture
conditions. This also emphasizes the importance of studying
functional intracellular pathways within a 3D environment
that mimics the tissue composition.
 
Results
 
Integrin 
 
 
 
v promotes melanoma cell 
survival in 3D-collagen
 
Previous studies indicated a role for integrin 
 
 
 
v
 
 
 
3 in mela-
noma cell survival both in 3D collagen in vitro and in hu-
man skin in vivo (Montgomery et al., 1994; Petitclerc et al.,
1999). To elucidate potential molecular mechanisms for integrin
 
 
 
v
 
 
 
3-mediated melanoma cell survival, we used M21 and M0
melanoma cell lines with or without integrin 
 
 
 
v. We character-
ized and compared the cell surface expression of integrin 
 
 
 
v
 
 
 
3
and of the integrin 
 
 
 
3 subunit in these cells by flow cytometry
(Fig. 1 A). These melanoma cells were then applied in a 3D
dermal collagen gel model enriched in collagen type I. Integrin
 
 
 
2
 
 
 
1 is a major receptor for collagen type I, mediating initial
M21 cell adhesion and spreading onto collagen type I, but
when collagen is degraded, the exposure of cryptic RGD sites
renders collagen type I to also allow binding of integrin 
 
 
 
v
 
 
 
3
(Montgomery et al., 1994). To control the potential effect of in-
tegrin 
 
 
 
v expression on integrin 
 
 
 
2
 
 
 
1, the cell surface ex-
pression of integrin 
 
 
 
2
 
 
 
1 was analyzed by flow cytometry.
However, we detected no differences in integrin 
 
 
 
2
 
 
 
1 levels
between the different integrin 
 
 
 
v-positive and 
 
 
 
v-negative
M21 subpopulations (unpublished data), indicating that alter-
ations of integrin 
 
 
 
v did not affect integrin 
 
 
 
2
 
 
 
1 and thereby
did not affect the capability to attach to collagen type I. M21
(integrin 
 
 
 
v
 
 
 
) and M21L (integrin 
 
 
 
v
 
 
 
) cells were then incu-
bated in 3D-collagen and analyzed for apoptosis using An-
nexin-V staining. We found that M21L (
 
 
 
v
 
 
 
) cells underwent
apoptosis to a much higher degree as compared with M21
(
 
 
 
v
 
 
 
) cells after 3–7 d of exposure in 3D-collagen (Fig. 1, B
and C), confirming previous findings that integrin 
 
 
 
v is critical
for M21 melanoma cell survival in 3D-collagen (Montgomery
et al., 1994). It should be noted that only low levels of apopto-
sis were observed in M21 (
 
 
 
v
 
 
 
) and M21L (
 
 
 
v
 
 
 
) cells under
2D culture conditions (d 0). Among different experiments, the
number of apoptotic M21L (
 
 
 
v
 
 
 
) cells ranged between 30 and
70% and the onset of apoptosis in these cells varied somewhat
in time and was typically clearly visible after 5 d in 3D-col-
lagen (unpublished data). In addition, similar results were ob-
tained by TUNEL staining (unpublished data). The role of inte-
grin 
 
 
 
v in melanoma cell survival was also addressed in M0
cell variants, an independent set of melanoma cells either lack-
ing integrin 
 
 
 
v (M0) or expressing high levels of wt integrin
 
 
 
v (M0-
 
 
 
v) (Chen et al., 1995). M0 (
 
 
 
v
 
 
 
) and M0-
 
 
 
v (
 
 
 
v
 
 
 
)
cells displayed low levels of apoptosis under 2D culture condi-
tions (d 0) (Fig. 1 D). However, M0 (
 
 
 
v
 
 
 
) cells became apop-
totic to a clearly higher degree as compared with M0-
 
 
 
v (
 
 
 
v
 
 
 
)
after culture in 3D-collagen for 3–5 d, indicating a role for inte-
grin 
 
 
 
v also in the survival of these melanoma cells in 3D-col-
lagen. Altogether, these results suggest an essential role for in-
tegrin 
 
 
 
v in control of melanoma cell survival.
 
Melanoma cell integrin 
 
 
 
v regulates 
caspase-9 but not caspase-8
 
Unligated integrin 
 
 
 
v
 
 
 
3 may induce epithelial cell apoptosis in
3D-collagen by recruitment and activation of caspase-8 (Stu- 
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pack et al., 2001). To examine potential caspase activation of
integrin 
 
 
 
v-positive and 
 
 
 
v-negative melanoma cells cultured
in 3D-collagen, we analyzed the presence of cleaved (active)
caspases 8 and 9 in M21 (
 
 
 
v
 
 
 
), M21L (
 
 v ), M0 ( v ), and
M0- v ( v ) cells (Fig. 2, A and B). We found no cleaved
caspase-8 in any of these four melanoma cell types when cul-
tured in 3D-collagen, whereas caspase-8 cleavage was clearly
visible in cycloheximide-treated Jurkat cells serving as positive
control. Interestingly, caspase-9 were cleaved to a higher de-
gree in integrin  v-negative M21L and M0 cells as compared
with integrin  v-positive M21 and M0- v cells, respectively,
in 3D-collagen, indicating that loss of integrin  v leads to acti-
vation of caspase-9. Given that caspase-9 is active in the mito-
Figure 1. Integrin  v is required for melanoma cell survival in 3D-collagen. (A) Integrin  v 3 (left) and  3 subunit (right) expression characterized by
flow cytometry in the melanoma cells used in this work. The M1 gate marks positive integrin staining as compared with the negative control (not depicted).
(B) Apoptosis was detected with Annexin-V staining in integrin  v-positive M21 and  v-negative M21L cells cultured in 3D-collagen for the indicated times
of 3–7 d. The displayed staining profiles are representative among three independent experiments. M1 marks Annexin-V positive cells as compared with
the control (left row) and the given numbers represent the quantification of the fraction of Annexin-V positive cells in the displayed representative experiment.
(C and D) Bar graphs display apoptosis in M21 ( v ) and M21L ( v ) cells (C) and in M0 ( v ) and M0- v ( v ) (D) cells cultured under 2D conditions
(d 0) and within 3D-collagen for the indicated times. Each graph in C and D represents the mean   SD of Annexin-V positive cells among three independent
experiments (*  P   0.05; **  P   0.01; as compared with M21 (C) or M0- v (D) cells using unpaired two tailed t test).
Figure 2. Regulation of melanoma cell caspase cleavage by integrin  v
in 3D-collagen. Cleaved caspase-8 and caspase-9 were detected by
immunoblotting in the integrin  v-positive and  v-negative melanoma
M21 ( v ) and M21L ( v ) cells (A) as well as M0 ( v ) and M0- v
( v ) cells (B) cultured under 2D conditions (d 0) and within 3D-collagen
for the indicated times. Active caspase-8 from cycloheximide-treated Jurkat
cells served as a positive control for caspase-8 cleavage. Detection of actin
served as loading control. The displayed blots are representative among
three independent experiments.JCB • VOLUME 167 • NUMBER 4 • 2004 748
chondrial apoptotic pathway (Green and Kroemer, 1998), this
suggests that the observed apoptosis in M21L ( v ) and M0
( v ) cells might be mediated via mitochondria.
Melanoma cell integrin  v inhibits p53 
activity in 3D-collagen
Active p53 can induce the mitochondrial apoptotic pathway
(Vousden and Lu, 2002) and activation of p53 has also been
associated with block of integrin  v 3 during angiogenesis
(Strömblad et al., 1996, 2002). Therefore, we investigated
whether integrin  v may also regulate p53 activity in mela-
noma cells cultured in 3D-collagen. Using electrophoretic mo-
bility shift analysis (EMSA), we examined p53 DNA-binding
activity by detecting specific p53 supershift bands with an anti-
p53 mAb. First, we verified the specificity by specific and non-
specific competition (Fig. 3 A). Then, p53 activities were ex-
amined in M21 ( v ) and M21L ( v ) cells after exposure in
3D-collagen. We found no difference in p53 activity between
M21 ( v ) cells and M21L ( v ) cells before exposure in
3D-collagen (d 0), indicating that p53 activity is not regulated
by melanoma cell integrin  v under 2D culture conditions.
However, the p53 activity was clearly higher in M21L ( v )
cells as compared with M21 ( v ) cells after 5–7 d in 3D-col-
lagen (Fig. 3 B), whereas p53 protein levels displayed no dif-
ference (Fig. 3 C). Consistently, we found that the p53 activity
was higher in M0 ( v ) cells than in M0- v ( v ) cells after
exposure in 3D-collagen (Fig. 3 D), but without any change in
p53 protein levels (Fig. 3 E). Together, our results demonstrate
that melanoma cell integrin  v inhibits p53 DNA-binding ac-
tivity within a 3D dermal collagen environment.
Posttranslational modifications, including phosphoryla-
tions and acetylations, are very important mechanisms for reg-
ulation of p53 activity (Vousden, 2002; Brooks and Gu, 2003).
To elucidate whether posttranslational modifications of p53
were regulated by integrin  v, we examined potential phos-
phorylations of p53 at Ser15 and Ser20 and potential acetylation
at Lys382 in integrin  v-positive and  v-negative melanoma
cells cultured in 3D-collagen. We found that phosphorylation
Figure 3. Integrin  v inhibits p53 activity in 3D-collagen.
(A) Nuclear extracts from integrin  v-negative M21L cells
cultured in 3D-collagen for 5 d were used for detecting
p53 DNA-binding activity by EMSA. Specific p53 super-
shift was obtained by anti-p53 mAb Pab421. Specific or
nonspecific competition was generated by incubating the
nuclear extracts with the 
32P-labeled probe in the pres-
ence or absence of 50-fold excess of unlabeled specific
or nonspecific oligonucleotides. (B and D) p53-DNA
binding activity was detected by EMSA in M21 ( v )
and M21L ( v ) cells (B) and in M0 ( v ) and M0- v
( v ) cells (D) under 2D conditions (d 0) or within 3D-
collagen for the indicated times. Large bar graphs show
quantifications of p53 DNA-binding activity EMSA super-
shift bands displayed immediately below. Boxed bar
graphs show the mean   SD of the ratio of p53 DNA-
binding activity bands between M21L ( v ) and M21
( v ) (B) or between M0 ( v ) and M0- v ( v ) (D) at
each time point based on three to four independent experi-
ments as described in Materials and methods. (*  P  
0.05; **  P   0.01, as compared with the corresponding
p53 DNA-binding activity ratios ( v / v ) at d 0 using
unpaired two-tailed t test). (C and E) p53 protein levels
were determined by Western blotting in M21 ( v ) and
M21L ( v ) cells (C) and in M0 ( v ) and M0- v ( v )
cells (E). Bar graphs show mean   SD of quantifications
of p53 protein levels relative to actin loading control from
three independent experiments. (F and G) Phosphorylated
p53 at Ser 15 and Ser 20 were detected by Western
blotting in M21 ( v ) and M21L ( v ) cells (F) and in
M0 ( v ) and M0- v ( v ) cells (G). The protein levels
of p53 and actin served as controls. (H–O) The levels of
acetylated p53-K382, p300, PUMA, Apaf1, Bax, and
Bcl-2 proteins were detected by Western blotting in M21
( v ) and M21L ( v ) cells (H, J, L, and N) and in M0
( v ) and M0- v ( v ) cells (I, K, M, and O) cultured un-
der 2D conditions (d 0) or in 3D-collagen for the indi-
cated times. Bar graphs (H and I) show quantifications of
p53-K382-Ac bands relative to total p53 levels of the
blots shown below, whereas bar graphs in J–M show
quantifications of the respective targeted protein bands
relative to the corresponding actin levels in blots dis-
played below the respective graph. Statistical analyses
were performed using t-test by analyzing the ratios be-
tween the M21L and M21 or M0 and M0- v values at
each time point compared with the corresponding ratios
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of p53 Ser20 was not altered by integrin  v (Fig. 3, F and G).
Although phosphorylation of p53 Ser15 showed a lower level
in M0- v ( v ) as compared with M0 ( v ) cells, this differ-
ence was not found when comparing M21 ( v ) and M21L
( v ) cells in 3D-collagen (Fig. 3 F), indicating that differ-
ences in phosphorylation of p53 Ser15 is not responsible for
the observed regulation of p53 activity. Importantly, melanoma
cell integrin  v inhibited acetylation of p53-K382 in 3D-col-
lagen, an acetylation known to promote p53 activity, whereas
the p53 protein levels remained constant (Fig. 3, H and I).
Given that p53-K382 is an acetylation site for the cofactor
p300, p300 protein levels were also quantified. Similar to
acetylation of p53-K382, the levels of p300 were reduced in in-
tegrin  v-positive M21 and M0- v cells as compared with the
 v-negative M21L and M0 cells, respectively, within 3D-col-
lagen (Fig. 3, J and K). This suggests that integrin  v controls
p300 levels in melanoma cells and that this regulation of p300
might be responsible for the differences in p53-K382 acet-
ylation. Given that p53 functions as a transcriptional acti-
vator, with transcriptional targets playing critical roles in p53-
induced apoptosis (Vousden and Lu, 2002), we also examined
the potential transcriptional p53 downstream targets PUMA,
Apaf1, Bax, and Bcl-2, all known to be involved in apoptosis
regulation. We found that PUMA protein levels were signifi-
cantly increased in integrin  v-negative M21L and M0 cells as
compared with those in  v-positive M21 and M0- v cells, re-
spectively, (Fig. 3, L and M), thus correlating with the p53-
DNA binding activities (Fig. 3, B and C). However, the protein
at d 0 as described in Materials and methods based on
three independent experiments. p53-K382-Ac (H and I):
P   0.001 for M21L/M21 at d 7 and M0/M0- v at d 3
and d 5; P   0.05 for M21L/M21 at d 3. p300 (J and K):
P   0.001 for M0/M0- v at d5; P   0.05 for M21L/
M21 at d 5 and d 7 and for M0/M0- v at d 3. PUMA
(L and M): P   0.001 for M21L/M21 at d 5; P   0.05
for M21L/M21 at d 7 and M0/M0- v at d 5. Displayed
blots and gel shifts are representative among at least
three independent experiments.JCB • VOLUME 167 • NUMBER 4 • 2004 750
Figure 4. Suppression of p53 compensates for the lack of integrin  v for
melanoma cell survival and tumor growth. (A) Apoptosis was analyzed by
Annexin-V staining in M21L-p53His175 clones (Lp53His175), M21L ( v )
and M21 ( v ) cells, cultured under 2D conditions (day 0) and within 3D-col-
lagen for the indicated times. The bar graph (top) shows the quantifications of
Annexin-V staining of one representative among three independent experi-
ments. p53 activities were detected by EMSA in the indicated cells cultured in
3D-collagen for 5 d (bottom) to control for suppression of p53 activity by p53-
His175 within the 3D collagen model used. (B–D) Melanoma cells were injected
s.c. into the back of C57/BL mice as described in Materials and methods. (B)
Photographs show representative mice from each group 25 d after tumor cell
injections. (C) The graph shows the mean tumor volumes for each group of
mice over time (n   7). (D) The wet weights were measured in dissected tumors
after 25 d. The graph shows mean weight   S.D. for each group (n   7; P  
0.05, unpaired two-tailed t test). (E) M21 ( v ), M21L ( v ), and five individual
M21L-p53-siRNA clones (Lp53siRNA) were cultured under 2D conditions (d 0)
and within 3D-collagen for the indicated times. Apoptosis was detected by
Annexin-V staining. The Western blots for p53 and actin protein levels are
shown in the vertical display for the cells indicated immediately to the left of
each lane. The displayed results are representative among three independent
experiments. (F) The protein levels of PUMA, Bax, and Apaf1 were detected by
Western blotting in M21L-p53-siRNA clones, M21L ( v ) and M21 ( v ) cells,
cultured in 3D-collagen for the indicated times, controlled by p53 and actin levels.INTEGRIN  V-MEDIATED P53 INACTIVATION IN MELANOMA CELL SURVIVAL • BAO AND STRÖMBLAD 751
levels of Apaf1, Bax, or Bcl-2 were not regulated by integrin
 v in these melanoma cells within 3–7 d in 3D-collagen (Fig.
3, N and O).
Inactivation of p53 compensates for lack 
of integrin  v in melanoma cell survival 
and tumor growth
We then examined whether the regulation of p53 activity by inte-
grin  v could functionally mediate the role of integrin  v in mel-
anoma cell survival in 3D-collagen and tumor growth in vivo. To
this end, we blocked integrin  v-negative M21L cell p53 activity
by stably transfecting a dominant negative (dn) p53-His175
cDNA. A number of p53-His175 expressing clones were identi-
fied using Western blotting (unpublished data). The M21L-p53-
His175 clones, M21L ( v ) and M21 ( v ) cells were cultured
in 3D-collagen and analyzed for apoptosis. In contrast to the pa-
rental M21L ( v ) cells, all four M21L-p53His175 clones sur-
vived to a similar degree as the integrin  v-positive M21 cells
(Fig. 4 A, top). To control for the inhibitory effect of p53-His175
in these clones within 3D-collagen, p53 DNA-binding activities
were analyzed after 5 d in 3D-collagen using EMSA (Fig. 4 A,
bottom). These results indicate that block of p53 function by
p53-His175 compensates for the lack of integrin  v in mela-
noma cell survival. Furthermore, M21 ( v ) and M21L ( v )
cells as well as two of the M21L-p53-His175 clones were in-
jected subcutaneously (s.c.) into the back of C57/BL nude mice,
to test if block of p53 function could compensate for lack of inte-
grin  v in melanoma tumor growth in vivo. Consistent with pre-
vious studies (Felding-Habermann et al., 1992), M21 ( v )
cells formed large tumors, whereas M21L ( v ) only formed
small or no tumors at all (Fig. 4, B–D). Importantly, M21L
( v ) cells overexpressing dn p53-His175 formed tumors to a
similar extent and with a similar growth rate as the integrin  v-
positive M21 cells (Fig. 4, B–D). This indicates that inhibition of
p53 is essential for melanoma tumor growth.
However, it can be argued that dn constructs are not en-
tirely specific. Therefore, in separate experiments, p53 protein
levels were knocked down by stable overexpression of p53-
small interfering RNA (siRNA). A number of M21L ( v )
clones with stable expression of p53-siRNA were identified by
detection of p53 protein levels, showing that p53 protein levels
were almost wiped out (Fig. 4 E, vertical blot). However, sup-
pression of p53 did not impact on integrin  v 3 or integrin
 2 1 expression levels as detected by flow cytometry (unpub-
lished data). The M21L-p53siRNA clones, M21L ( v ) and
M21 ( v ) cells were then cultured in 3D-collagen and ana-
lyzed for apoptosis. In agreement with the results using dn p53,
apoptosis was significantly decreased in the M21L-p53siRNA
clones in 3D-collagen as compared with the parental M21L
( v ) cells and were instead similar to that of M21 ( v ) cells
(Fig. 4 E), suggesting that inhibition of p53 by p53-siRNA
compensated for loss of integrin  v in promotion of melanoma
cell survival. Thereby, our results indicate that regulation of
p53 activity mediates the function of integrin  v in melanoma
cell survival and tumor growth. Furthermore, to investigate
whether the p53 transcriptional targets PUMA, Bax, and Apaf1
might be regulated by p53 within 3D-collagen, their protein
levels were determined in the M21L-p53siRNA clones and
compared with M21L ( v ) and M21 ( v ) cells (Fig. 4 F).
The PUMA levels were reduced in M21L-p53siRNA clones as
compared with the parental M21L ( v ) cells in 3D-collagen,
whereas the levels of Bax and Apaf1 were not affected. This in-
dicates that PUMA might be a direct p53 downstream target in
melanoma cells in 3D-collagen.
Integrin  v-dependent MEK1 activity is 
required for melanoma cell survival in 
3D-collagen
Integrin   v 3 ligation promotes sustained activation of the
MEK1–ERK1/2 signaling pathway in vascular cells during an-
giogenesis (Eliceiri et al., 1998). Because of an active mutation
of BRAF, MEK1 and ERK1/2 are constitutively activated in
most melanoma cell lines under conventional 2D culture condi-
tions (Satyamoorthy et al., 2003). However, it is unclear if inte-
grin  v 3 may play a role in regulation of MEK1 and ERK1/2
activities in melanoma cells within a 3D environment. To ad-
dress this question, we examined MEK1 and ERK1/2 activities
in integrin  v-positive M21 and integrin  v-negative M21L
cells cultured in 3D-collagen. We detected no differences in
MEK1 or ERK1/2 activities between M21 ( v ) and M21L
( v–) cells under 2D culture conditions (Fig. 5 A, d 0). How-
ever, both MEK1 and ERK1/2 activities were markedly re-
duced in  v-negative M21L cells in contrast to  v-positive
M21 cells after 3–7 d of exposure in 3D-collagen (Fig. 5 A).
This indicates that whereas MEK1 and ERK1/2 is active in mel-
anoma cells under 2D culture conditions, integrin  v appears to
be needed for activation of MEK1 and ERK1/2 within a 3D en-
vironment. To examine the potential role of MEK1 signaling
in integrin  v-mediated melanoma cell survival, we blocked
MEK1 activity by treatment of integrin  v-positive M21 cells
with two specific MEK1 inhibitors, PD98059 and U0126.
Both inhibitors strongly induced apoptosis in M21 ( v ) cells
within 3D-collagen (Fig. 5, B and C), but with no changes in in-
tegrin  v 3 cell surface expression levels (not depicted). This
shows that integrin  v-dependent MEK1 signaling is required
for melanoma cell survival within a 3D environment.
To examine if block of MEK1 might induce p53 activity
within 3D-collagen, p53 DNA-binding activity and p53 protein
levels were examined in PD98059-treated integrin  v-positive
M21 cells (Fig. 5 D). However, both p53 activity and protein
levels were not induced by PD98059, but instead appeared to be
inhibited, demonstrating that the suppression of p53 activity by
integrin  v is not mediated by MEK1 signaling. In addition,
overexpression of a constitutively active (ca) mutant MEK1
(S218D/S222D) did not affect p53 activity in integrin  v-nega-
tive M21L cells (unpublished data), likewise indicating that
MEK1 does not mediate integrin  v-dependent p53 inactivation.
Suppression of p53 rescues MEK1 activity 
in integrin  v-negative melanoma cells
Given that MEK1 signaling did not act as a mediator of inte-
grin  v-dependent regulation of p53, we instead tested if sup-
pression of p53 might affect MEK1–ERK1/2 activity within
3D-collagen. We used the M21L ( v ) clones stably express-JCB • VOLUME 167 • NUMBER 4 • 2004 752
ing dn p53-His175 or p53-siRNA. Under 2D culture conditions
(d 0), we observed no influence on MEK1 by expression of
p53-His175 or p53-siRNA (unpublished data). However, sur-
prisingly, suppression of p53 by both p53-His175 and p53-
siRNA expression rescued MEK1 and ERK1/2 activities in in-
tegrin  v-negative M21L cells to similar levels as in integrin
 v-positive M21 cells within 3D-collagen (Fig. 6, A and B).
However, no changes were observed at MEK1 or ERK1/2 pro-
tein levels (Fig. 6, A and B), indicating that the suppression of
p53 in cells lacking integrin  v instead only influenced MEK1
and ERK1/2 activities. Furthermore, we examined whether
MEK1 activity was still required for melanoma cell survival af-
ter knockdown of p53 by siRNA and thus whether MEK1 may
functionally act downstream of p53 in regulation of melanoma
cell survival. As shown in Fig. 6 C, M21L-p53siRNA ( v )
clones that normally survived to the same extent as M21 ( v )
cells underwent apoptosis to a high degree when treated with
the MEK1 inhibitor PD98059 within 3D-collagen, indicating
that these cells were still dependent on MEK1 for survi-
val. This indicates that MEK1 is critical and functionally acts
downstream of p53 in integrin  v-mediated melanoma cell sur-
vival. However, overexpression of ca MEK1 (S218D/S222D)
did not rescue M21L ( v ) cell survival in 3D-collagen (un-
published data). Given that block of p53 rescued the same
M21L ( v ) cells, this suggests that p53 may act not only
through MEK1 regulation, but also through additional down-
stream pathways to induce melanoma cell apoptosis.
Discussion
Several reports have demonstrated that integrin-mediated cell–
matrix interactions trigger different signaling and cellular be-
havior in 3D environments as compared with regular 2D cul-
ture conditions (for reviews see Cukierman et al., 2002; Jacks
and Weinberg, 2002). Our results reveal another example of
how important a 3D environment can be for the cellular re-
sponse to integrins. We investigated regulatory mechanisms for
melanoma cell survival in a 3D dermal collagen model mim-
icking the pathophysiological environment of malignant mela-
noma in the dermis (Montgomery et al., 1994). Our results
showed that p53 activity as well as MEK1–ERK1/2 signaling
was regulated by integrin  v only within 3D-collagen. More-
over, integrin  v-mediated suppression of p53 activity func-
tionally controlled a MEK1-dependent melanoma cell survival
pathway. However, none of these components appeared to be
critical for regulation of cell survival in 2D cultures. Impor-
tantly, our results from the 3D-collagen gel model are similar
to our results on melanoma tumor growth in vivo, where sup-
pression of p53 activity rescued tumor growth of  v-integrin
negative melanoma cells that otherwise did not grow. Thus, in-
tegrin  v-mediated inhibition of p53 was essential for the con-
trol of melanoma cell survival within 3D-collagen in vitro as
well as for tumor growth in vivo. In fact, a similar pathway has
been implicated in angiogenesis, where integrin  v 3 antago-
nist-induced vascular cell apoptosis corresponded to induction
of p53 activity (Strömblad et al., 1996, 2002). Our results
might explain why melanoma that overexpresses integrin  v 3
appears to have an advantage for growth, survival, invasion,
and metastasis (Hsu et al., 1998; Petitclerc et al., 1999; Seftor
et al., 1999). However, the molecular mechanisms by which
melanoma cell integrin  v 3 regulates p53 activity remain
unclear.
Acetylations are known to be important modulators of
p53 activity (Brooks and Gu, 2003). We found that p53 acti-
Figure 5. Integrin  v-dependent MEK1 activity is required
for melanoma cell survival in 3D-collagen. (A) M21 ( v )
cells and M21L ( v ) cells were cultured under 2D condi-
tions (d 0) and within 3D-collagen for the indicated times.
The levels of active MEK1 and ERK1/2 as well as of total
MEK1 and ERK1/2 were detected by Western blotting,
with actin as control and the displayed blots are repre-
sentative among five experiments. (B and C) M21 ( v )
cells within 3D-collagen were treated with the MEK1
inhibitors PD98059 (B) and U0126 (C) or DMSO as a
vehicle control. Annexin-V staining detected apoptosis
and the bar graphs show the mean   SD of apoptotic
cells among three independent experiments (**  P   
0.01, as compared with vehicle control using unpaired
two-tailed t test). Phosphorylated ERK1/2 was detected
by Western blotting to control for the suppressive effect of
the MEK1 inhibitors. (D) p53 DNA-binding activities were
detected by EMSA and p53 protein levels determined
by Western blotting in M21 ( v ) cells treated with
PD98059 within 3D-collagen for 3–7 d. Phosphorylated
ERK1/2 was detected to monitor the inhibitory effect of
PD98059, and total ERK1/2 and actin levels were analyzed
as controls. Note that the exposure time in this EMSA
was longer than for EMSAs displayed in other figures
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vation caused by lack of integrin  v correlated to p53-K382
acetylation as well as to regulation of p300. Acetylation of
p53-K382 by p300 is known to be an important regulatory
mechanism for p53 activity (Sakaguchi et al., 1998) and p300
levels are mainly regulated by the rate of proteasomal degra-
dation (Poizat et al., 2000). Given our recent finding that
ligation of integrins induces specific proteasomal proteolysis
(Bao et al., 2002), it is possible that melanoma cell integrin
 v 3 may specifically regulate the proteasomal turnover of
p300 and thereby modulate acetylation of p53-K382 and p53
activity. However, it remains to be elucidated if p300-medi-
ated p53-acetylation is functional in integrin  v-mediated
regulation of p53 activity.
A notable fact is that most malignant melanoma harbor
wt p53, but display strong resistance to chemotherapy and
radiation, suggesting that p53 may be dysfunctional (Satya-
moorthy et al., 2001). A number of ways have been suggested
to result in the dysfunction of wt p53 in melanoma, including
defective downstream effectors. For example, Apaf1, an es-
sential downstream component in p53-induced apoptosis, has
been suggested to be lost in malignant melanoma leading to
melanoma cells escaping from apoptosis and thereby ex-
hibiting strong chemotherapy resistance (Soengas et al.,
2001). However, our results displayed no loss of Apaf1 pro-
tein in M21 melanoma cells. Moreover, caspase-9 cleavage
was still regulated by integrin  v, suggesting no defect in
Apaf1 activity because Apaf1 is needed for caspase-9 cleav-
age (Zou et al., 1999). However, in preliminary experiments,
we tested the integrin  v 3 cell surface expression in 13 dif-
ferent malignant melanoma cell lines carrying wt p53 and
found that eleven of these cell lines expressed high levels of
integrin  v 3, whereas four out of five melanoma cell lines
tested with mutant p53 had low or no integrin  v 3 ex-
pression (unpublished data). This indicates a correlation be-
tween the p53 mutational status and integrin  v 3 expression
in malignant melanoma cells. Moreover, integrin  v 3 is
known to be highly expressed in most dermal malignant mel-
anoma in patients (Albelda et al., 1990; Seftor et al., 1999;
Van Belle et al., 1999). Together, with the role for integrin  v
in suppressing wt p53 activity presented here, integrin  v-
mediated inactivation of wt p53 might help to explain the lack
of need for malignant melanoma p53 mutations in vivo.
Concomitant with enhanced p53 activity, PUMA levels
were increased upon lack of integrin  v, but were reduced
when also p53 was suppressed, implicating that melanoma cell
PUMA might be a downstream target of p53 (Jeffers et al.,
2003). Although the levels of Bax protein were not regulated in
response to loss of integrin  v, a transcription-independent reg-
ulation of bax by p53 might induce apoptosis (Chipuk et al.,
2004). Considering that caspase-9 is activated by loss of inte-
grin  v, and also that caspase-9 is known to be essential for
p53-induced apoptosis (Soengas et al., 1999), loss of integrin
 v might trigger a mitochondrial apoptotic pathway, which is
commonly associated with increased PUMA and active cas-
pase-9 (Wang, 2001). However, unlike the suggested caspase-
8–dependent apoptotic pathway that may be caused by unli-
gated integrin  v 3 in epithelial cells (Stupack et al., 2001),
our results rule out activation of caspase-8 in the induction of
melanoma cell apoptosis caused by lack of integrin  v.
Integrin-activated Raf–MEK1–ERK1/2 signaling regu-
lates various cellular functions, including cell survival (Howe
et al., 2002) and melanocytes need anchorage to activate
ERK1/2 signaling (Conner et al., 2003). However, although
most melanoma cells cultured under 2D conditions display
active ERK1/2 induced by a ca BRAF V599E mutation
(Satyamoorthy et al., 2003), we found that melanoma cell
MEK1–ERK1/2 signaling depended on integrin  v within 3D-
collagen. Importantly, this integrin  v-mediated signaling path-
way was necessary for melanoma cell survival in 3D-collagen
because block of MEK1 activity induced melanoma cell apop-
tosis, whereas a previous study found no such effect by block-
ing MEK1 under 2D culture conditions (Smalley and Eisen,
2002). This is another example of how our results display dif-
ferences in signal transduction and cell survival triggered by
cell to 3D matrix interactions as compared with 2D culture
conditions. Furthermore, our results are also consistent with an
in vivo need for integrin  v 3 for sustained vascular cell
ERK1/2 activation during angiogenesis (Eliceiri et al., 1998).
Recently, integrin  v 3 was found to trigger FAK as well as
PAK1-mediated c-Raf-S338 phosphorylation in angiogenic en-
dothelial cells leading to activation of MEK and ERK (Hood et
Figure 6. p53 controls a MEK1-dependent melanoma cell survival pathway.
(A and B) The levels of activated and total MEK1 as well as activated and
total ERK1/2 were detected by Western blotting in M21 ( v ), M21L
( v ), and in M21L-p53His175 clones (Lp53His175) (A) and M21L-p53-
siRNA clones (Lp53siRNA) (B) after 5 d of culture within 3D-collagen. The
p53 protein levels were measured as control for the effect of p53-siRNA
and actin levels as control. (C) M21L ( v ) clones stably expressing
p53-siRNA (Lp53siRNA) were treated with the MEK1 inhibitor PD98059
in 3D-collagen for 5 d and compared with untreated M21L ( v ) and
M21 ( v ) cells. Apoptosis was detected by Annexin-V staining. The
displayed results are representative among three independent experiments.JCB • VOLUME 167 • NUMBER 4 • 2004 754
al., 2003). However, we found neither FAK-Y397 or c-Raf-
S338 phosphorylation, nor PAK1 kinase activity to be regu-
lated by integrin  v in melanoma cells in 3D-collagen (un-
published data). Because we did not observe any integrin
 v-dependent regulation of FAK activity within 3D-collagen,
our results do not favor the possibility that integrin-activated
FAK may suppress p53 in the regulation of apoptosis (Ilic et
al., 1998), although we used a different cell type and a different
model compared with previous studies. However, surprisingly,
we found that inactivation of p53 functions upstream of MEK1
in regulating integrin  v-mediated melanoma cell survival. p53
can transcriptionally activate MAPK phosphatases, including
PAC1, which may play a role in p53-dependent apoptosis by
dephosphorylating and inactivating ERK (Yin et al., 2003).
However, we found no regulation of PAC1 levels by p53
within our system (unpublished data).
Several ECM proteins can be recognized by  v-integrins,
including vitronectin, denatured collagen type I, and osteopon-
tin (Strömblad and Cheresh, 1996). Although integrin  2 1 is
a major receptor for collagen type I, M21 melanoma cells are
capable of degrading native collagen type I to expose cryptic
RGD sites for integrin  v 3 ligation, suggesting that degraded
collagen type I could be a functional ligand for melanoma cell
integrin  v-mediated cell survival (Montgomery et al., 1994).
Alternatively, given that osteopontin may be involved in mela-
noma progression from the radial growth phase to the vertical
growth phase (Sturm et al., 2002), and that overexpression of
osteopontin may promote melanocyte survival in 3D-collagen
(Geissinger et al., 2002), endogenously produced osteopontin
is another potential ligand for integrin  v within 3D-collagen.
It should be noted that although the dermis contains  90% col-
lagen type I, it also contains other types of collagen as well as
fibronectin and additional ECM components. Furthermore,
other cell types are present in the dermis in vivo and the col-
lagen density and assembly in vivo might also differ from the
used in vitro 3D-collagen model. Therefore, the used in vitro
model is not an exact replica of the dermis environment. How-
ever, importantly, our results obtained in the 3D collagen
model were consistent with our results obtained in vivo in
mouse skin, indicating that the in vitro 3D-collagen model is
valid for studies of molecular pathways involved in integrin  v
regulation of melanoma cell survival.
In conclusion, we have identified an integrin  v-depen-
dent melanoma cell survival pathway within 3D dermal col-
lagen. We found that integrin  v caused inactivation of wt
p53, which functionally promoted melanoma cell survival
and tumor growth in vivo. Simultaneously, integrin  v-medi-
ated activation of MEK1 signaling was also required for mel-
anoma cell survival. Surprisingly, we found that whereas p53
acts downstream of integrin  v, it also regulates MEK1 activ-
ity in the same functional melanoma cell survival pathway.
Although the melanoma cells depended on this integrin  v-
mediated pathway for survival in 3D environments, they were
independent of this pathway under 2D culture conditions,
stressing the importance of studying the role of cell to matrix
interactions and their functional signaling pathways within
3D contexts.
Materials and methods
Cell culture and 3D collagen gel model
Human melanoma M21 cells expressing integrin  v and a subpopulation
of these cells, M21L cells lacking integrin  v were obtained by negative
selection using FACS with an anti- v mAb (Felding-Habermann et al.,
1992). Human melanoma M0 cells lacking the integrin  v subunit and
M0- v cells expressing wt integrin  v were gifts from M. Ginsberg (Uni-
versity of California, San Diego, San Diego, CA; Chen et al., 1995).
Cells were cultured in RPMI 1640 medium containing 5% FCS, 2 mM
L-glutamine and 50  g/ml gentamycin. Before culturing cells in a 3D-col-
lagen, cells were adapted into RPMI1640 medium with 1% Nutridoma-SP
(Boehringer-Mannheim) for 3 wk as described previously (Montgomery et
al., 1994). Dermal collagen type I gels (Cohesion) were also prepared as
described previously (Montgomery et al., 1994) and in certain experi-
ments, 50  M PD98059 (Calbiochem) or 5  M U0126 (Calbiochem)
was mixed into the collagen before polymerization. For the extraction of
cells from the collagen gel, 0.25% clostridial collagenase (Worthington) in
PBS was used to digest the collagen gel for 10–15 min at 37 C. After
washes with cold PBS, cells were used for further analysis.
Flow cytometric determination of integrin expression and apoptosis
1   10
6 cells were incubated with 1  g/ l of anti- v 3 mAb LM609
(CHEMICON International, Inc.), 5  g/ l of anti- 3 mAb AP3 (GTI) or 10
 g/ l anti- 2 1 mAb 12F1 (CHEMICON International, Inc.) for 1 h at
RT. After washing, cells were incubated with FITC-conjugated goat anti–
mouse IgG (1:50; Jackson ImmunoResearch Laboratories) for 30 min and
analyzed by flow cytometry with CellQuest Software (Becton Dickinson).
The fraction of apoptotic cells was detected by flow cytometry after stain-
ing with Annexin-V FITC as described by the manufacturer (Biosource In-
ternational), or by TUNEL using an in situ Cell Death Detection kit (Boeh-
ringer-Mannheim).
Stable transfections
Expression vectors with human p53 dn mutant p53-His175 (pCMV-Neo-
BAM-p53-His175) and p53-siRNA (pSUPER-p53) were gifts from K.
Wiman (Karolinska Institutet) and R. Agami (The Netherlands Cancer Insti-
tute, Amsterdam, Netherlands), respectively. M21L ( v ) cells were trans-
fected with 10  g of p53-His175 cDNA or cotransfected with 10  g of
pSUPER-p53 and 1  g of pCI-neo plasmid using Lipofectamine 2000 (In-
vitrogen). 72 h after transfections, cells were treated with 600  g/ml of
G-418 (Invitrogen). After 14 d, G418-resistant clones were picked, ex-
panded and eventually selected based on p53 protein levels and p53
DNA binding activities. ca MEK1 S218D/S222D cDNA, a gift from P.
Gerwins (Uppsala University, Uppsala, Sweden), was stably introduced
into M21L ( v ) cells by the same method. Positive clones were selected
according to induced levels of phosphorylated ERK1/2.
EMSA
Nuclear extracts were prepared and subjected to EMSA as described pre-
viously (Selivanova et al., 1996). The protein concentrations of the crude
nuclear extracts were determined using a BCA protein quantification kit
(Pierce Chemical Co.) using BSA as a standard. 
32P-end–labeled double
stranded oligonucleotides containing the following human p53 recogni-
tion sequence was used: (5 -CAGGCATGTCTGCAGGCAAAGGCAT-
GTCTG-3 ). For specific or nonspecific competition, the corresponding un-
labeled oligonucleotides or random oligonucleotides were added together
in reactions. For supershift, anti-p53 mAb Pab421 (Oncogene) was used
and performed as described previously (Selivanova et al., 1996). The
analysis was finalized by autoradiography or by a phosphor-imager
(Packard).
Western blotting
Cell lysates, protein determination, and Western blotting were performed
as described previously (Bao and Strömblad, 2002). The following pri-
mary antibodies were used: anti-p53 mAb (DO1), anti-bax pab (N-20),
anti-MEK1 pab (C-18), and anti-PAC1 pab (N-19) were purchased from
Santa Cruz Biotechnology, Inc.; anti-p53 mAb (Pab421), anti-p53 pab
(Ab-7), anti-acetylated p53 Lys382 pab (Ab-1), anti-p300 pab (N-15),
anti-PUMA pab (Ab-1), and anti–caspase-8 mAb (clone 1–3) were pur-
chased from Oncogene Research Products; anti–phospho-MEK1/2 pab
(Ser 217/221), anti–phospho-ERK1–ERK2 pab (Thr202/Thr204), anti–
phospho-p53 pab (Ser 15), anti–phospho-p53 pab (Ser 20), and anti–
caspase-9 pab were purchased from New England Biolabs, Inc.; anti-
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was obtained from the Developmental Studies Hybridoma Bank at the Uni-
versity of Iowa.
In vivo tumor growth
Animal experiments were performed according to a permit from the Stock-
holm South ethical committee in Sweden. C57BL6 black nude female mice
(6–8 w) were obtained from M&B. Melanoma cells (1   10
6) were in-
jected s.c. at the back of the mice. The tumor size was measured every
other day with calipers and tumor volumes were calculated by the formula
0.52   length   width
2. The wet weight of dissected tumors was deter-
mined at the end of experiments.
Statistical analyses
The following statistical analyses were performed for the results repre-
sented in Fig. 3. Although the integrin  v-negative cells constantly dis-
played higher p53 DNA-binding activity as compared with the integrin
 v-positive cells after exposure in 3D-collagen, the absolute values (magni-
tude) and the time of onset of p53 activity varied between experiments.
Therefore, we calculated the ratio of p53 activity between  v-negative
cells and the corresponding  v-positive cells at each time point (Fig. 3, B
and D, closed bars) and performed a statistical analysis of these ratios
compared with the corresponding ratios at the start of the experiments (d
0) by use of unpaired two-tailed t test. Likewise, the ratios between results
obtained from integrin  v-negative and integrin  v-positive cells were used
for the statistical analyses of Western blot results represented in Fig. 3 (H–M)
in the same manner. Statistical evaluations of experiments shown in other
figures were performed as described in the figure legends.
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